

Serum Fetuin A Level in Patients with NAFLD and Chronic HCV

Thesis

**Submitted for Partial Fulfillment of MSc Degree in
Internal Medicine**

Presented by

Roqaya Mahmmmed Hussein Salman

M.B.B.Ch

Misr University for Science and Technology

Under Supervision of

Prof. Dr./ Mohamed Ali Marie Makhoul

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

Assist Prof. Dr./ Shereen Abo Bakr Saleh

Assistant Professor of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

Dr./ Mohamed Magdy Salama

Lecturer of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

Dr./ Mohamed Ali Awadeen

Lecturer of Internal Medicine and Gastroenterology

Faculty of Medicine, Misr University for Science and Technology

Faculty of Medicine
Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

In the beginning I have to thank Allah who gave me power and strength to carry out this work.

It is a great pleasure to express my sincere gratitude and highest appreciation to Prof. Dr.Mohamed Marie Makhlouf, Professor of Gasrtoenterology and Hepatology, Faculty of Medicine Ain Shams University under whose guidance and constant supervision this work has been prepared. Actually, more and above words fail to cope with his overwhelming kindness and moral support that was a great help to me.

I would like to express my sincere gratitude to Dr. Shereen Abou Bakr Saleh, Assistant Professor of Gasrtoenterology and Hepatology, Faculty of Medicine Ain Shams University for her generous help, valuable suggestions and keen supervision and great effort to achieve this work.

My deepest appreciations are to Dr. Mohamed Magdy Salama. Lecturer of Gasrtoenterology and Hepatology, Faculty of Medicine, Ain Shams University, for his considerable help and continuous guidance.

My special thanks and deep appreciation to Dr Mohamed Ali Awadeen, Lecturer of Gasrtoenterology and Hepatology, Faculty of Medicine, Misr University For Science and Technology for his great support and encouragement throughout this work.

Also great thanks to all dear professors from whom I learned as well as my dear colleagues who supported me during this work.

Finally, I dedicate this work to my family (my parents, my brothers and my husband)who was of great help, gave me a lot of guidance and support.

Roqaya Mahmmed

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iv
List of Abbreviations.....	vii
Introduction	1
Aim of the Work	16
Review of Literature	
☞ Nonalcoholic Fatty Liver Disease	17
☞ Hepatitis C	47
☞ Myokines, Adipokines and Hepatokines	66
☞ Fetuin A.....	88
Patients and Methods	104
Results.....	113
Discussion.....	147
Summary.....	155
Conclusion	158
Recommendation	159
References	160
Appendex.....	205
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Criteria for clinical diagnosis of the MS	25
Table (2):	Symptoms, Signs, and Laboratory Features of NAFLD	29
Table (3):	Main extra hepatic manifestations of hepatitis C Virus infection.....	54
Table (4):	Interpretation of HCV assays	58
Table (5):	Approved HCV drugs in the European Union in 2016.....	62
Table (6):	Treatment recommendations for HCV- monoinfected or HCV/HIV coinfectd patients with chronic hepatitis C without cirrhosis, including treatment – naïve patients and patients who failed on a treatment based on PegIFN- α and ribavirin (RBV)	63
Table (7):	Treatment recommendations for HCV- monoinfected or HCV/HIV patients with hepatitis C with compensated (child – Pugh A) cirrhosis, including treatment – naïve patients and patients who failed on a treatment based on PegIFN- α and ribavirin (RBV)	64
Table (8):	Reference values of Fetuin A levels	109
Table (9):	Comparison between control group and patients group regarding demographic data (age, sex and BMI).....	114
Table (10):	Comparison between control group and patients group regarding compenents of CBC (HB, TLC and PLT)	115

List of Tables (Cont...)

Table No.	Title	Page No.
Table (11):	Comparison between control group and patients group regarding liver function tests (AST, ALT, BIL T, BIL D, Alb, PT and INR) and Alfa-Feto p	116
Table (12):	Comparison between control group and patients group regarding kidney function tests (NA, K, BUN and CREAT)	117
Table (13):	Comparison between control group and patients group regarding HBA1C, FBS, S. CHO and S. TAG.....	118
Table (14):	Comparison between control group and patients group regarding APRI, FIB4 , FETUIN A.....	120
Table (15):	Comparison between control group and patient subgroups (NAFLD, HCV) regarding demographic data (age, sex, BMI)	122
Table (16):	Comparison between control group and patients subgroups regarding componentes of CBC (HB, TLC and PLT).....	124
Table (17):	Comparison between control group and patients subgroups (NAFLD and HCV) regarding liver function tests (AST, ALT, BIL T, BIL D, ALB, PT, INR and Alpha-feto P).....	125
Table (18):	Comparison between control group and patients subgroups (NAFLD and HCV) regarding kidney function tests (NA, K, BUN and CREAT)	126

List of Tables (Cont...)

Table No.	Title	Page No.
Table (19):	Comparison between control group and patients subgroups (NAFLD and HCV) regarding (HBA1C, FBS, S. CHO and S. TAG).....	127
Table (20):	Comparison between control group and patient subgroups (NAFLD and HCV) regarding APRI, FIB4 score and FETUIN A.	129
Table (21):	Correlation of Fetuin A with the studied parameters in all patients group and subgroups	131
Table (22):	Correlation of serum cholesterol with the studied parameters in all patients group and subgroups (NAFLD, HCV).....	136
Table (23):	Correlation of serum triglyceride with the studied parameters in all patients group and subgroups (NAFLD, HCV).....	139

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Two-hit hypothesis of nonalcoholic fatty liver disease.....	20
Figure (2):	Interplay among environmental and genetic factors in the development of nonalcoholic fatty liver disease	22
Figure (3):	Effect of insulin resistance on formation of fatty liver	23
Figure (4):	Ectopic fat accumulation and lipotoxicity in various organs	24
Figure (5):	Classifications of myokines, adipokines and hepatokines.....	66
Figure (6):	Comorbiddties of physical inactivity.	67
Figure (7):	Effect of obesity and type II diabetes on different body organs.....	68
Figure (8):	Effect of myokines on liver and white adipose tissue.....	70
Figure (9):	Effect of obesity on release of different types of myokines.	76
Figure (10):	Effect of anti-inflammatory adipokines on liver, muscle and pancreas.	77
Figure (11):	Effect of secretion of hepatokines on liver.....	84
Figure (12):	Structure of Fetuin A.....	90
Figure (13):	Comparison between control group and patients group regarding S. cholesterol and S. triglyceride.....	119
Figure (14):	Comparison between control group and patients group regarding fetuin A level.....	121

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (15):	Comparison between control group and patient subgroups (NAFLD and HCV) regarding BMI.	123
Figure (16):	Comparison between control group and patients subgroups (NAFLD and HCV) regarding serum cholesterol level.	128
Figure (17):	Comparison between control group and patients subgroups (NAFLD and HCV) regarding serum triglyceride level.	128
Figure (18):	Comparison between control group and patients subgroups regarding fetuin A level.	130
Figure (19):	Correlation between fetuin A and INR in all patients group.	132
Figure (20):	Correlation between fetuin A and serum cholesterol in all patients group.	133
Figure (21):	Correlation between fetuin A and serum triglyceride in all patients group.	133
Figure (22):	Correlation between fetuin A and serum cholesterol in NAFLD group.	134
Figure (23):	Correlation between fetuin A and serum triglyceride in NAFLD group.	134
Figure (24):	Correlation between fetuin A and serum cholesterol in hepatitis C virus group.	135
Figure (25):	Correlation between fetuin A and serum triglyceride in hepatitis C virus group.	135
Figure (26):	Correlation between serum cholesterol and fetuin A levels in all patients.	137

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (27):	Correlation between serum cholesterol and fetuin A levels in NAFLD group.	138
Figure (28):	Correlation between serum cholesterol and fetuin A levels in hepatitis C virus with fatty liver group.....	138
Figure (29):	Correlation between serum triglyceride and fetuin A levels in all patients.....	140
Figure (30):	Correlation between serum triglyceride and fetuin A levels in NAFLD group.	141
Figure (31):	Correlation between serum triglyceride and fetuin A levels in hepatitis C virus with fatty liver group.....	141
Figure (32):	Cut off point of serum fetuin A.	143
Figure (33):	Cut off point of serum fetuin A in diagnosing NAFLD group.	144
Figure (34):	Cut off point of serum fetuin A in diagnosing HCV group.	145
Figure (35):	The best cut off point of serum fetuin A in differentiating NAFLD group from HCV group.	146

Introduction

Introduction

Non-alcoholic fatty liver disease (NAFLD) encompasses the simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. NAFLD is considered a growing epidemic, not only in the western world, but worldwide in part due to obesity and insulin resistance leading to liver accumulation of triglycerides and free fatty acids (*Benedict and Zhang, 2017*).

NAFLD place a strain on the medical system and its resources, it also is associated with a 34%-69% chance of dying over the next 15 years when compared with the general population (*Patel and Saxena, 2016*).

Hepatic steatosis is a feature of chronic HCV infection and a potentially finalistic condition favoring the persistence and replication of HCV thus be a useful marker for identifying those HCV patients at higher risk of liver disease progression, development of extra-hepatic diseases, and, possibly, reduced response rate to novel antivirals (*Adinolfi et al., 2016*).

As HCV is an RNA virus with little potential for integration of its genetic material into the host genome, HCV contributes to HCC development in an indirect way, through induction of chronic inflammation, and directly, by means of viral factors. HCV-induced HCC development is a multi-step process that involves establishment of chronic HCV infection,

persistent chronic hepatic inflammation, progressive liver fibrogenesis (*Billerbeck et al., 2013*).

Chronic infection with HCV is the leading cause of end-stage liver disease, hepatocellular carcinoma (HCC) and liver-related death in Egypt. HCV causes chronic hepatitis in 60%–80% of the patients, and 10%–20% of those patients develop cirrhosis over 20–30 years of HCV infection. About 1%–5% of the patients with liver cirrhosis may develop liver cancer and 3%–6% may decompensate during the following 20–30 years. The risk of death in the following year after an episode of decompensation is between 15% and 20% (*Westbrook, 2014*).

Adipose tissue is now established as an active endocrine organ that has a big role in secretion of adipokines. Altered adipokine production and secretion can provide a link between adipose tissue dysfunction and obesity related disorders. as they are responsible for regulation of the whole body metabolism because they are involved in impaired insulin sensitivity or secretion, inflammation, fat distribution, satiety, and appetite, as well as endothelial dysfunction and atherosclerosis (*Kloting and Bluher, 2014*).

Fetuin A is a glycoprotein formed by liver cells and secreted into the serum in high concentration. Fetuin A is formed during embryogenesis. It stimulates bone remodelling, regulates the process of osteogenesis and it inhibits ectopic calcification (*Szweras et al., 2002*).

An association between insulin resistance and type 2 diabetes in individuals with high serum Fetuin A levels was reported (*Stefan et al., 2006*).

Fetuin A is an independent risk factor for developing diabetes (*Eraso et al., 2010*). Additionally, further studies have emphasized that there may be an association between Fetuin A levels and peripheral arterial disease (PAD) (*Lorant et al., 2011*).

Fetuin A is secreted into the blood stream and it is deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin A acts as an important circulating inhibitor of ectopic calcification that is a frequent complication of many degenerative diseases (*Schafer et al., 2003*).

Human Fetuin A represents a natural inhibitor of tyrosine kinase activity of the insulin receptor. Fetuin A may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation and may be a novel therapeutic target in the treatment of type 2 diabetes, obesity, and other insulin-resistant conditions (*Rasul et al., 2012*).

Association has been proposed to exist among increased of concentration of Fetuin A, obesity and fatty liver. This is explained by the fact that fetuin A induces insulin resistance which is the primary abnormality leading to both metabolic syndrome and fatty liver disease. Accumulation of it in adipocytes leads to increased fetuin secretion (*Reinehr and Roth, 2008*).

Fetuin A levels would associate with this early indicator of NAFLD, as well as serum liver enzymes levels circulating Fetuin A levels elevates in subjects with high liver fat and decrease in liver fat was accompanied by decrease in Fetuin A concentrations (*Stefan et al., 2006*).

Fetuin A can be used in the diagnosis and treatment of joint arthritis as it is considered an acute phase glycoprotein, which directed scientific attention regarding its anti-inflammatory role (*Pappa et al., 2017*).